Catalog No.
Product Name
Application
Product Information
Citations
-
ADC Linker
FL118-C3-O-C-amide-C-NH2 serves as an effective ADC linker, playing a crucial role in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Its application in ADC development supports research in targeted cancer therapies. -
ADC/PROTAC Linker
N-Boc-PEG7-alcohol is a PEG-based linker primarily utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates targeted drug delivery by enhancing the solubility and stability of therapeutic compounds. Its versatile applications in chemical biology make it a valuable tool for researchers aiming to develop novel targeted therapies. -
ADC/PROTAC Linker
m-PEG10-amine is a non-cleavable 10 unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This linker enhances the solubility and stability of conjugated biomolecules, facilitating targeted delivery and improved therapeutic efficacy. It is particularly valuable in research applications focusing on ADC development and targeted protein degradation strategies. -
PROTAC Linkers
Propargyl-PEG4-Tos is a PEG-based linker specifically designed for the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a cleavable linker in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutic agents. This compound features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc), allowing for efficient conjugation with azide-containing molecules. Its versatile applications make it a valuable tool in chemical biology and drug development research. -
ADC/PROTAC Linker
N-Boc-PEG6-alcohol is a PEG-based linker designed for antibody-drug conjugate (ADC) and PROTAC applications. This cleavable linker facilitates the synthesis of PROTACs, allowing for targeted degradation of specific proteins. Its unique structure provides enhanced solubility and stability, making it suitable for various biochemical studies focused on targeted therapies and protein regulation. -
ADC Linker
trans-Sulfo-SMCC is a non-cleavable crosslinker designed for antibody-drug conjugates (ADCs), known for its membrane permeability. This reagent facilitates stable linkage between antibodies and cytotoxic agents, enhancing therapeutic efficacy while ensuring targeted delivery. It is ideal for research applications focused on ADC development and the investigation of targeted drug delivery systems. -
ADC Linker
PPC-NB is a glutathione-cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents in targeted cancer therapy, enhancing the therapeutic index of ADCs. Its unique properties make it suitable for research applications focused on improving drug delivery systems and developing novel therapeutic strategies in cancer treatment. -
ADC Linker
Mal-PEG1-Val-Cit-PAB-PNP is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). This compound features a polyethylene glycol (PEG) spacer, allowing for flexible and stable conjugation to antibodies. It is specifically engineered to facilitate the release of cytotoxic agents in targeted therapy applications, making it valuable in cancer research and drug development. -
ADC Linker
PC SPDP-NHS carbonate ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of therapeutic agents to antibodies, allowing for targeted drug delivery. Its functionality promotes the release of the drug in the desired cellular environment, enhancing therapeutic efficacy. Researchers utilize this linker in studies focused on improving the specificity and effectiveness of ADC-based therapies. -
ADC Payload
NMS-P528 is a Duocarmycin derivative that functions as an antibody-drug conjugate (ADC) payload. This compound exhibits potent cytotoxic activity, providing a mechanism to selectively target and eliminate cancer cells. It can also be utilized in the synthesis of NMS-P945, facilitating advanced research in targeted therapeutic strategies. Its role in ADC development underscores its significance in cancer research applications. -
ADC Payload
N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine functions as a tubulin polymerization inhibitor and serves as an effective antibody-drug conjugate (ADC) payload. This compound disrupts microtubule dynamics, which can lead to cancer cell apoptosis. Its application in ADC development is valuable for targeted cancer therapies, enhancing the efficacy of specific antibodies against tumor cells. -
ADC Cytotoxin
Azonafide-PEABA is a cytotoxic agent specifically designed for use in antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity through its ability to interfere with cellular processes, leading to apoptosis in targeted cancer cells. Azonafide-PEABA is ideal for research applications focused on the development and optimization of ADC therapies in oncology. -
ADC Payload
7-Methylol-9-methoxy-10-F-camptothecin is a camptothecin derivative that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity by inhibiting topoisomerase I, leading to DNA damage and subsequent cancer cell death. Its utility in ADC synthesis makes it a valuable tool for targeted cancer therapy research and development. -
ADC Cytotoxin
NH2-methylpropanamide-Exatecan TFA is a methylpropanamide-modified form of Exatecan, an effective ADC cytotoxin targeting DNA topoisomerase I. With an IC50 of 2.2 μM, this compound plays a crucial role in cancer research by facilitating the development of antibody-drug conjugates (ADCs) for targeted therapies. The modification enhances its utility in the synthesis of ADCs, making it a valuable reagent for studies focused on therapeutic interventions in oncology. -
ADC Cytotoxin
INX-SM-6 is a potent ADC cytotoxin that selectively targets and inhibits the production of pro-inflammatory cytokines. It effectively reduces LPS-induced IL-1β production in human peripheral blood mononuclear cells (PBMCs), making it valuable for research focused on inflammation and immune response modulation. This reagent is suitable for studies aimed at developing targeted therapies for inflammatory diseases. -
ADC Cytotoxin
MMAF-methyl ester functions as an ADC (antibody-drug conjugate) cytotoxin by delivering potent therapeutic agents directly to target cells. This compound exhibits significant cytotoxic activity, disrupting cellular processes and inducing apoptosis in cancer cells. It is primarily utilized in research applications focusing on the development and optimization of targeted cancer therapies, enhancing the efficacy of antibody-based treatments. -
ADC Cytotoxin
Corixetan is a potent thorium chelator utilized in antibody-drug conjugate (ADC) applications. It effectively forms stable complexes with Th-227, providing adequate in vivo stability for targeted cytotoxic delivery. This compound is valuable for research in ADC development and radiotherapy, specifically aiming to improve therapeutic outcomes in cancer treatment. -
ADC Linker
SC209 intermediate-2 is an ADC linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound serves as an essential intermediate for the cytotoxin SC209, enabling targeted delivery of therapeutic agents to cancer cells. SC209 intermediate-2 plays a crucial role in enhancing the efficacy of ADCs in research applications focused on cancer treatment and drug development. -
ADC Cytotoxin
10NH2-11F-Camptothecin TFA is a derivative of Camptothecin designed for use as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits potent anticancer activity, making it suitable for the development of targeted cancer therapeutics. Its application in ADC formulation allows for enhanced specificity and efficacy in targeting tumor cells. -
ADC Cytotoxin
Dov-Val-Dil-OH is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. It exhibits potent cytotoxic activity by selectively killing tumor cells upon internalization. This compound is primarily utilized in the development and evaluation of ADCs, allowing researchers to study its efficacy in various cancer models. -
ADC Cytotoxin
Exatecan-2-(aminomethoxy)acetamide-Gly-Fmoc is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. This compound exerts its cytotoxic effects primarily through the inhibition of topoisomerase I, leading to DNA damage and subsequent cell death in malignant cells. It is utilized in research for the development of innovative ADCs, optimizing delivery mechanisms for enhanced tumor selectivity and therapeutic efficacy. -
Drug-Linker Conjugate For ADC
LP-6 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound integrates an Eg5 inhibitor with a linker, facilitating targeted drug delivery and enhancing therapeutic efficacy. It is suitable for research applications focused on the development and optimization of ADCs in cancer therapy. -
ADC Linker
BCN-linker-DXd 2 is a specialized ADC (antibody-drug conjugate) linker designed for targeted delivery of cytotoxic agents to cancer cells. This compound facilitates the conjugation of drugs to antibodies, enhancing specificity and reducing off-target effects in cancer therapy. It is applicable in research focused on ADC development and optimization for improved therapeutic efficacy against various types of tumors. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADCs). It employs the potent tubulin inhibitor MMAF, which is covalently linked via the cathepsin-cleavable peptide MC-Val-Cit-PAB. This compound exhibits significant antitumor activity, making it valuable for research applications in cancer therapy and development of targeted drug delivery systems. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-MMAE is a conjugate designed for use in antibody-drug conjugate (ADC) synthesis, incorporating a drug-linker element. The DBCO component facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. The included MMAE moiety, a potent inhibitor of tubulin polymerization derived from dolastatin 10, exhibits significant mitotic inhibition. This reagent is ideal for advancing research in targeted cancer therapies by enabling the precise delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-GGFG-Dxd is a drug-linker conjugate targeting antibody-drug conjugates (ADCs) with potent antitumor activity derived from the DNA topoisomerase I inhibitor Dxd. This compound utilizes a cleavable linker, DBCO-PEG4-GGFG, which enhances selective delivery of the therapeutic agent. DBCO-PEG4-GGFG-Dxd serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it a valuable tool in bioconjugation applications. -
Drug-Linker Conjugate for ADC
MC-VA-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide linker, MC-VA-PAB, with Exatecan, a potent inhibitor of DNA topoisomerase I, to enhance therapeutic efficacy. Synthesis of MC-VA-PAB-Exatecan-based ADCs demonstrates significant antitumor activity, making it a valuable tool for cancer research and drug development. -
Drug-Linker Conjugates for ADC
DL-01 formic is a versatile drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It facilitates the covalent attachment of cytotoxic agents to antibodies, enhancing selective targeting of cancer cells. This reagent plays a crucial role in the development and optimization of ADC formulations for targeted cancer therapies, providing a means to improve therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
PB038 is a drug-linker conjugate featuring a polyethylene glycol (PEG) unit and a cleavable linker connected to Exatecan. This compound is designed to facilitate the targeted delivery of cytotoxic agents in antibody-drug conjugates (ADCs), enhancing therapeutic efficacy while minimizing off-target effects. PB038 is suitable for research applications focused on cancer therapeutics and drug development involving ADC technology. -
Drug-Linker Conjugates for ADC
Mc-VC-PAB-SN38 is a cleavable drug-linker conjugate that combines a linker (Mc-VC-PAB) with the potent DNA topoisomerase I inhibitor SN38. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), providing a targeted approach for delivering therapeutic agents to malignant cells. Its unique structure facilitates the release of SN38 within the cellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through the action of MMAE, a tubulin polymerization inhibitor. The incorporation of the cleavable ADC linker MC-betaglucuronide enables targeted delivery and release of MMAE in tumor cells, enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate For ADC
MC-VA-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates the linker peptide MC-VA-PABC with the potent tubulin polymerization inhibitor MMAE, facilitating targeted delivery of the cytotoxic agent. It plays a crucial role in enhancing the therapeutic efficacy of ADCs in cancer research by selectively delivering MMAE to tumor cells while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Gly-Mal-GGFG with the cytotoxic agent Deruxtecan 2-hydroxypropanamide, facilitating targeted delivery of therapeutic agents to cancer cells. It is primarily utilized in research focused on improving the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugates for ADC
AZ14170133 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound comprises a cytotoxic payload, a topoisomerase 1 inhibitor, linked for effective targeted delivery. AZ14170133 is utilized in the synthesis of ADCs such as AZD9592 and AZD8205, making it a valuable tool for cancer research focused on developing innovative therapeutic strategies. -
Drug-Linker Conjugates for ADC
Gly3-VC-PAB-MMAE is a cleavable drug-linker conjugate comprising the linker Gly3-VC-PAB and the potent tubulin inhibitor MMAE. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling targeted delivery of MMAE to cancer cells. Its unique structure allows for the selective release of the cytotoxic agent in the tumor microenvironment, making it valuable in cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features DM1, a potent microtubule-disrupting agent, linked by the Mal-VC-PAB linker, which enhances targeted delivery to tumor cells. Mal-VC-PAB-DM1 exhibits significant antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that combines a cleavable PEG linker with the potent tubulin polymerization inhibitor MMAF. The DBCO moiety facilitates efficient synthesis through click chemistry, specifically strain-promoted alkyne-azide cycloaddition (SPAAC), allowing for precise conjugation to azide-containing biomolecules. This reagent is essential for enhancing the therapeutic efficacy of ADCs by enabling targeted delivery of cytotoxic agents. -
Anti-Nectin-4 ADC Linker
Mal-PEG8-Val-Ala-PAB-Exatecan is an anti-Nectin-4 antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of chemotherapeutic agents. This compound enables precise conjugation to Nectin-4 polypeptides, allowing for enhanced therapeutic efficacy in cancer research applications. Its unique structure promotes stability and release characteristics, making it suitable for studying the effects of ADCs in various tumor models. -
Drug-linker Conjugate for ADC
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a cleavable linker, NH2-PEG3-VC-PAB, which is linked to the potent tubulin inhibitor Monomethyl auristatin E (MMAE). This reagent is essential for facilitating targeted delivery and localized cytotoxicity in cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker that facilitates selective release of the potent tubulin inhibitor MMAE upon internalization by target cells. It is ideal for research aimed at improving the therapeutic index of ADCs through targeted delivery and enhanced cytotoxicity against cancer cells. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing MMAF as a potent tubulin polymerization inhibitor. The conjugate features a cleavable linker, DBCO-PEG4, which facilitates the selective release of MMAF within target cells. DBCO-PEG4-MMAF serves as a click chemistry reagent, containing a DBCO group that efficiently engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-modified molecules, making it a valuable tool for targeted therapeutics in cancer research. -
Drug-Linker Conjugate for ADC
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, targeting microtubules to exert potent antitumor effects. The compound features the anti-microtubule agent Eribulin, which is covalently linked via the Mal-(CH2)5-Val-Cit-PAB linker. This strategic design enhances the therapeutic efficacy of Eribulin while minimizing systemic toxicity, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA Topoisomerase I with an IC50 of 2.2 μM, which interferes with DNA replication and induces apoptosis in cancer cells. Its application in ADCs allows for targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
DBCO-(PEG2-VC-PAB-MMAE)2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, linked to a cleavable DBCO-(PEG2-VC-PAB)2 linker. The DBCO group enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, facilitating targeted delivery of cytotoxic agents. Its application is crucial for research in cancer therapeutics, particularly in enhancing the efficacy and selectivity of ADCs. -
ADC Linker
SuO-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that combines SuO-Glu-Val-Cit-PAB with the potent tubulin inhibitor MMAE. This compound enables targeted delivery of MMAE via ADC technology, facilitating selective cytotoxicity in cancer research. SuO-Glu-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, providing a strategic approach to enhance therapeutic efficacy while minimizing off-target effects. -
Cleavable ADC Linker
Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective drug delivery by connecting antibodies to the cytotoxic agent MMAE, enhancing therapeutic efficacy while minimizing off-target effects. Its PEG4 moiety ensures improved solubility and stability, making it suitable for research applications in cancer therapy and targeted delivery systems. -
Drug-Linker Conjugates for ADC
Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Mal-PEG4-VC-PAB with the cytotoxic agent DMEA-PNU-159682, which derives from metabolites of nemorubicin (MMDX) processed by liver microsomes. It exhibits strong cytotoxicity, making it suitable for targeted cancer therapies in research focused on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The linker comprises Gly-Gly-Phe-Gly-NH-O-CO, which is attached to Exatecan, a potent inhibitor of DNA topoisomerase I. This compound exhibits significant potential in cancer research, facilitating targeted delivery and enhanced therapeutic efficacy in anticancer treatments. -
Drug-Linker Conjugates for ADC
Doxorubicin-SMCC is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring a non-cleavable linker and the anthracycline antibiotic Doxorubicin. Doxorubicin targets DNA topoisomerase II, interrupting DNA replication and transcription processes, which leads to cell death in rapidly dividing cancer cells. This reagent is valuable for research applications focused on targeted cancer therapies and the development of innovative drug delivery systems. -
Drug-Linker Conjugate For ADC
TCO-PEG4-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (TCO-PEG4-VC-PA) that facilitates the release of the potent tubulin inhibitor MMAE upon cellular internalization. TCO-PEG4-VC-PAB-MMAE incorporates a TCO group suitable for inverse electron demand Diels-Alder (iEDDA) reactions, enabling highly specific conjugation with tetrazine-containing molecules, thus enhancing therapeutic efficacy in targeted treatments.
